BioDiscovery and AGRE Enter into a Co-Promotion Agreement
News Sep 19, 2012
BioDiscovery, Inc. and the Autism Genetic Resource Exchange (AGRE) have signed a co-promotion agreement. This agreement allows AGRE to provide copy number and allelic event data to its research users through BioDisovery’s Nexus DB platform.
“We are very excited about working with the AGRE consortium,” said Dr. Soheil Shams, President of BioDiscovery, Inc.
Dr. Shams continued, “There has been a tremendous investment in collection and generation of genomic data to better understand Autism and our agreement with AGRE will enable researchers a new way to more easily access and rapidly analyze this data. We hope that the efficient visualization and statistical analysis methods in Nexus Copy Number™ and Nexus DB™ will help to accelerate advancement of research in this very important area.”
“BioDiscovery Nexus Copy Number will allow researchers in our network to easily and quickly navigate through the array data which we make available” said Clara Lajonchere. Ph.D., VP of Clinical Program at Autism Speaks.
Lajonchere continued, “While we have provided our microarray data in other formats and will continue to do so, Nexus DB offers AGRE researchers an efficient and user-friendly interface for viewing and analyzing the thousands of microarray experiments which have been done using the AGRE subjects. Our hope is that this will accelerate the discovery of genes that play a role in autism by simplifying the process of analyzing data.”
BioDiscovery’s software is platform independent and available for Mac OS X, Linux and Windows operating systems.
BioDiscovery Nexus Copy Number is the leading platform independent and user friendly application for DNA copy number analysis.
Nexus Copy Number can integrate and process together, in a single project, data from commercial array platforms such as Agilent, Affymetrix, Illumina, Roche NimbleGen, Next Gen read depth, as well as custom arrays.
With its free access to a web-based repository for querying, and storing genomic data from any location across the globe, Nexus Copy Number is a powerful solution for large groups such as special consortia and collaborative research networks like AGRE.
AGRE is the largest private collection of genotype and phenotype information for over 2,600 individuals with ASD and their family members.
Over the last 15 years, AGRE has amassed an extremely robust clinical dataset that includes detailed medical, developmental, morphological, demographic and behavioral information making it one of the most comprehensive autism family repositories.
There are 350 active researchers from 21 countries that have used the AGRE resource to publish over 202 scientific papers, making it the most widely accessed resource for genetic studies of autism.
Currently, AGRE stores genotyping data for over 1,000 multiplex families using two different microarray analysis platforms, Affimetrix and Illumina, and the availability of those datasets to researchers has been instrumental in moving the field forward.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.